BofA downgraded Fresenius Medical (FMS) to Underperform from Neutral with a price target of EUR 38, down from EUR 50, citing limited visibility on when patient volumes will recover and margin risks in 2025-26 due to ACA subsidies expiring and a mix shift to value-based care. The firm thinks upcoming potential catalysts are well appreciated and won’t drive meaningful near-term upside, the analyst added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Appoints Joseph Turk to Management Board
- Fresenius Medical appoints Joseph Turk as CEO, Care Enablement
- Cautious Hold Rating for Fresenius Medical Care Amidst Stagnant Growth and Uncertain Recovery
- Fresenius Medical Care Boosts Value-Based Care with Strategic Investment and Leadership Change
- Fresenius Medical downgraded to Sell from Neutral at UBS